DEVELOPMENT OF IMAGE ENHANCEMENT RADIOPHARMACEUTICALS FOR THERAPY

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 该实验室进行图像增强剂和治疗用放射性药物的开发研究。该实验室位于华盛顿大学医学院放射学系Mallinckrodt研究所放射科学部，拥有8名教职员工、5名博士后研究助理、2名研究生和约16名支持人员。该实验室操作两台回旋加速器和一台直线加速器，用于生产放射性核素，并维持最先进的设备，用于合成、分离和质量控制成像和治疗剂。在开发用于正电子发射断层扫描（PET）、单光子发射断层扫描（SPECT）和磁共振（MR）成像应用的无机和有机化合物方面进行了研究。放射性药物也被开发用于靶向放射治疗的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This laboratory carries out research on the development of image enhancement agents and radiopharmaceuticals for therapy. The laboratory is in the Division of Radiological Sciences in the Mallinckrodt Institute, Department of Radiology, Washington University Medical School and has eight faculty members, five post doctoral Research Associates, two graduate students and approximately 16 support staff. The laboratory operates two cyclotrons and a linear accelerator for radionuclide production and maintains state-of-the-art equipment for synthesis, separation and quality control of agents for imaging and therapy. Research is carried out in development of both inorganic and organic compounds for positron emission tomographic (PET), single photon emitted tomographic (SPECT) and magnetic resonance (MR) imaging applications. Radiopharmaceuticals are also developed for the investigation of targeted radiotherapy.